iBio Inc
For the period ended Jun 30, 2024. Filed Sep 20, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Sep 20, 2024
IBIO$0.78-1.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets – June 30, 2024 and 2023
Consolidated Balance Sheets** **
(In Thousands, except share and per share amounts)
| | | | | | | |
|---|---|---|---|---|---|---|
| | | | | | | |
| | | June 30, 2024 | June 30, 2023 | |||
| | | | | | | |
| Assets | | | | | | |
| Current assets: | | | | | | |
| Cash and cash equivalents | | $14,210 | | $4,301 | ||
| Restricted cash | | | — | | | 3,025 |
| Subscription receivable | | | — | | | 204 |
| Promissory note receivable and accrued interest | | | 713 | | | — |
| Prepaid expenses and other current assets | | 749 | | 664 | ||
| Current assets held for sale (see Note 3 - Discontinued Operations) | | | — | | | 18,065 |
| Total Current Assets | | 15,672 | | 26,259 | ||
| | | | | | ||
| Restricted cash | | | 215 | | | 253 |
| Promissory note receivable | | | 1,081 | | 1,706 | |
| Finance lease right-of-use assets, net of accumulated amortization | | 339 | | 610 | ||
| Operating lease right-of-use asset | | | 2,401 | | | 2,722 |
| Fixed assets, net of accumulated depreciation | | 3,632 | | 4,219 | ||
| Intangible assets, net of accumulated amortization | | | 5,368 | | 5,388 | |
| Security deposits | | | 26 | | | 50 |
| Total Assets | | $28,734 | | $41,207 | ||
| | | | | | ||
| Liabilities and Stockholders' Equity | | | | | ||
| Current liabilities: | | | | | ||
| Accounts payable | | $358 | | $1,849 | ||
| Accrued expenses | | 2,028 | | 4,561 | ||
| Finance lease obligations - current portion | | | 299 | | | 272 |
| Operating lease obligation - current portion | | | 436 | | | 389 |
| Equipment financing payable - current portion | | | 178 | | | 160 |
| Term promissory note - current portion | | | 218 | | | — |
| Insurance premium financing payable | | | 123 | | | — |
| Term note payable - net of deferred financing costs | | | — | | | 12,937 |
| Contract liabilities | | | 200 | | | — |
| Current liabilities related to assets held for sale | | — | | | 1,941 | |
| Total Current Liabilities | | 3,840 | | 22,109 | ||
| | | | | | ||
| Finance lease obligations - net of current portion | | | 53 | | | 351 |
| Operating lease obligation - net of current portion | | | 2,688 | | | 3,125 |
| Equipment financing payable - net of current portion | | | 63 | | | 241 |
| Term promissory note - net of current portion | | | 766 | | | — |
| | | | | | ||
| Total Liabilities | | 7,410 | | 25,826 | ||
| | | | | | ||
| Stockholders' Equity | | | | | ||
| Series 2022 Convertible Preferred Stock - $0.001 par value; 1,000,000 shares authorized at June 30, 2024 and June 30, 2023; 0 shares issued and outstanding as of June 30, 2024 and June 30, 2023 | | — | | — | ||
| Common stock - $0.001 par value; 275,000,000 shares authorized at June 30, 2024 and June 30, 2023; 8,623,676 and 1,015,505 shares issued and outstanding as of June 30, 2024 and June 30, 2023, respectively | | 9 | | 1 | ||
| Additional paid-in capital | | 335,162 | | 304,320 | ||
| Accumulated deficit | | | (313,847) | | (288,940) | |
| Total Stockholders’ Equity | | 21,324 | | 15,381 | ||
| | | | | | | |
| Total Equity | | 21,324 | | 15,381 | ||
| Total Liabilities and Stockholders' Equity | | $28,734 | | $41,207 | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.